Market News

Pfizer (NYSE: PFE) and BioNTech Seek FDA Nod For COVID Booster Shot For Children

On Monday, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced that they have submitted an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for a 10 -µg booster dose of its Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.

The companies also stated that they intend to submit an application seeking an extension of marketing authorization for the Omicron BA.4/BA.5-adapted bivalent vaccine targeting children ages 5 through 11 years to the European Medicines Agency (EMA).

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos